For research use only. Not for therapeutic Use.
AER-271 (CAT: I016669) is a phosphonate prodrug derivative of AER-270. It is specifically designed as an inhibitor of aquaporin-4 (AQP4), a water channel protein. AER-271 is primarily used for research purposes in the field of acute ischemic stroke. By targeting AQP4, it aims to modulate water movement in the brain and potentially reduce brain edema, which is a common complication of stroke. AER-271 is being investigated for its potential therapeutic applications in the treatment of acute ischemic stroke.
| Catalog Number | I016669 |
| CAS Number | 634913-39-6 |
| Molecular Formula | C₁₅H₉ClF₆NO₅P |
| Purity | ≥95% |
| Target | Aquaporin |
| Reference | [1]. Wallisch JS, et al. The aquaporin-4 inhibitor AER-271 blocks acute cerebral edema and improves early outcome in a pediatric model of asphyxial cardiac arrest. Pediatr Res. 2019 Mar;85(4):511-517.<br>[2]. Farr GW, et al. Functionalized Phenylbenzamides Inhibit Aquaporin-4 Reducing Cerebral Edema and Improving Outcome in Two Models of CNS Injury. Neuroscience. 2019 Apr 15;404:484-498. |
